Health Insurance (Pathology Services Table) Regulations 2005 Select Legislative Instrument 2005 No. 239
I, JOHN LANDY, Administrator of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973. Dated 20 October 2005 JOHN LANDY Administrator By the Administrator’s Command TONY ABBOTT Minister for Health and Ageing
Contents 1 Name of Regulations 4 2 Commencement 4 3 Health Insurance (Pathology Services Table) Regulations 2004 — repeal 4 4 Definitions 4 5 Pathology services table 4 Schedule 1 Table of pathology services 5 Part 1 Prescription of table 5 1A Prescription of table 5 Part 2 Rules of interpretation 5 1 Interpretation of table 5 2 Precedence of items 6 3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request 8 4 Services to which rule 3 does not apply 9 5 Item taken to refer only to the first service of a particular kind 10 6 Certain items not to apply to a service referred by 1 pathology practitioner to another 11 7 Items not to be split 13 8 Creatinine ratios — Group P2 (Chemical) 13 9 Thyroid function testing 13 10 Meaning of serial examinations or cultures 14 11 Investigation for hepatitis serology 14 12 Tests in Group P4 (Immunology) relating to antibodies 15 13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology) 15 14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances 16 15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items 19 16 Circumstances in which an item in Group P11 (Specimen referred) does not apply 19 17 Abbreviations 20 18 Certain pathology services to be treated as 1 service 20 19 Hepatitis C viral RNA testing 22 20 Haemochromatosis testing 22 21 Serum B12 and red cell folate testing 22 22 Nutritional and toxicity metals testing 22 23 Antineutrophil cytoplasmic antibody tests 23 24 Satisfying requirements described in pathology service 23 25 Limitation on certain items 24 26 Antigen detection 24 Part 3 Services and fees 25 Part 4 Abbreviations 69 Part 5 Complexity levels for histopathology items 105
1 Name of Regulations These Regulations are the Health Insurance (Pathology Services Table) Regulations 2005.
2 Commencement These Regulations commence on 1 November 2005.
3 Health Insurance (Pathology Services Table) Regulations 2004 — repeal The Health Insurance (Pathology Services Table) Regulations 2004 are repealed.
4 Definitions In these Regulations: Act means the Health Insurance Act 1973. this table means these Regulations.
5 Pathology services table The table of pathology services set out in Schedule 1 is prescribed for subsection 4A (1) of the Act.
Schedule 1 Table of pathology services (regulation 5)
Part 1 Prescription of table
1A Prescription of table For section 4A of the Act, these Regulations prescribe a table of pathology services that sets out: (a) in Part 2 — rules for interpretation of the table; and (b) in Part 3: (i) items of pathology services; and (ii) the amount of fees applicable for each item; and (c) in Parts 4 and 5 — additional supporting information.
Part 2 Rules of interpretation
1 Interpretation of table (1) In this table: item means: (a) an item mentioned, by number, in column 1 of: (i) Part 3; or (ii) Part 3 of the diagnostic imaging services table; or (iii) Part 3 of the general medical services table; and (b) in a reference immediately followed by a number — the item so numbered. patient episode means: (a) a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act: (i) on the same day; or (ii) if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days; whether the services: (iii) are requested by 1 or more practitioners; or (iv) are described in a single item or in more than 1 item; or (v) are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or (vi) are rendered on the same or different days; or (b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relate to the service. recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act. serial examinations means a series of examinations requested on 1 occasion whether or not: (a) the materials are received on different days by the approved pathology practitioner; or (b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner. (2) In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies. (3) A reference to a Group in the table includes every item in the Group and a reference to a Subgroup in the table includes every item in the Subgroup.
2 Precedence of items (1) If a service is described: (a) in an item in general terms; and (b) in another item in specific terms; only the item that describes the service in specific terms applies to the service. (2) Subject to subrule (3), if: (a) subrule (1) does not apply; and (b) a service is described in 2 or more items; only the item that provides the lower or lowest fee for the service applies to the service. (3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately. Application of items 74990 and 74991 (4) Despite subrules (1), (2) and (3): (a) if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and (b) if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in this table that applies to the service. (5) For items 74990 and 74991: bulk-billed, in relation to a pathology service, means: (a) a medicare benefit is payable to a person in respect of the service; and (b) under an agreement entered into under section 20A of the Act: (i) the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and (ii) the practitioner accepts the assignment in full payment of his or her fee for the service provided. Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84 (1) of the National Health Act 1953. unreferred service means a pathology service that: (a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and (b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights. (6) For item 74991: ASGC means the document titled Australian Standard Geographical Classification (ASGC) 2002, published by the Australian Bureau of Statistics, as in force on 1 July 2002. practice location, in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Medicare Australia CEO. regional, rural or remote area means an area classified as RRMAs 3-7 under the Rural, Remote and Metropolitan Areas Classification. Rural, Remote and Metropolitan Areas Classification has the meaning given by subrule 3 (1) of Part 2 of Schedule 1 to the general medical services table. SLA means a Statistical Local Area specified in the ASGC. SSD means a Statistical Subdivision specified in the ASGC.
3 Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request (1) In subrule (2), service includes assay, estimation and test. (2) Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if: (a) the services are listed in the same item; and (b) that item is not item 74990 or 74991; and (c) the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than 1 day.
4 Services to which rule 3 does not apply (1) Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66515, 66584 or 66800 if: (a) the service is rendered in relation to 1 or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and (b) the service is rendered to an inpatient of a hospital; and (c) the service is rendered in relation to each specimen as soon as possible after the specimen is taken; and (d) the account for the service is endorsed ‘Rule 3 Exemption’. (2) Rule 3 does not apply to any of the following pathology services: (a) estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy; (b) quantitative estimation of lithium for a patient undergoing lithium therapy; (c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy; (d) a service described in item 65070 in relation to
clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient; (e) a service described in any of items 66500 to 66515, in relation to methotrexate or leflunomide therapy of a patient; (f) quantitative estimation of urea, creatinine and electrolytes in relation to: (i) cis-platinum or cyclosporin therapy of a patient; or (ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital; (g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues; if: (h) under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and (i) the tests are performed within 6 months of the request; and (j) the account for the service is endorsed ‘Rule 3 Exemption’.
5 Item taken to refer only to the first service of a particular kind (1) For an item in Group P1 (Haematology): (a) if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and (b) if: (i) tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and (ii) specimen material from the patient episode is stored; and (iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material; the later tests and the earlier tests are taken to be part of 1 patient episode. (2) Items 65102 and 65108 apply only if a minimum of 6 units are issued for a patient’s care in any 1 day. (3) For items 65099 and 65102: compatibility tests by crossmatch means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.
6 Certain items not to apply to a service referred by 1 pathology practitioner to another (1) In this rule: designated pathology service means a pathology service in respect of tests relating to a single patient episode that are: (a) tests of the kind described in item 66695; or (b) tests of the kind described in item 66722; or (c) tests of the kind described in item 66800; or (d) tests of the kind described in item 66812; or (e) tests of the kind described in item 69384. (2) This rule applies in respect of a designated pathology service where: (a) an approved pathology practitioner (practitioner A) in an approved pathology authority: (i) has been requested to render the designated pathology service; and (ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and (iii) requests an approved pathology practitioner (practitioner B) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and (iv) renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and (b) the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66710, 66734, 66806, 66815 or 69399. (3) If this rule applies in respect of a designated pathology service: (a) item 66695, 66698, 66701, 66704, 66707, 66722, 66725, 66728, 66731, 66800, 66803, 66812, 69384, 69387, 69390, 69393 or 69396 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and (b) where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (4), the amount specified in item 66713, 66737, 66809, 66818 or 69402 (as the case requires) is payable for each test that the service comprises. (4) For paragraph (3) (b), the maximum number of tests to which item 66713, 66737, 66809, 66818 or 69402 applies is: (a) for item 66809: 3 – X; and (b) for item 66818: 2 – X; and (c) for item 66713, 66737 or 69402: 6 – X; where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made. (5) Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).
7 Items not to be split Except as stated in rule 6, the amount specified in an item is payable only to 1 approved pathology practitioner in respect of a single patient episode.
8 Creatinine ratios — Group P2 (Chemical) A pathology service mentioned in an item in Group P2 (Chemical) (except item 66500) that: (a) involves the measurement of a substance in urine; and (b) requires calculation of a substance/creatinine ratio; is taken to include the measurement of creatinine necessary for the calculation.
9 Thyroid function testing (1) For item 66719: abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level. (2) Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable for a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3). (3) The written statement from the medical practitioner must indicate: (a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or (b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or (c) that the patient is on drugs that interfere with thyroid hormone metabolism or function.
10 Meaning of serial examinations or cultures For an item in Group P3 (Microbiology): (a) serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not: (i) the materials are received on different days by the approved pathology practitioner; or (ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and (b) if: (i) tests are carried out in relation to a patient episode; and (ii) specimen material from the patient episode is stored; and (iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material; the later tests and the earlier tests are taken to be part of 1 patient episode.
11 Investigation for hepatitis serology (1) The fee applying in a single patient episode that includes any of items 69475, 69478 and 69481 is the fee specified for 1 only of those items. (2) Item 69478 applies to a service in relation to which: (a) a practitioner requests 2 tests for immune status or viral carriage; or (b) the clinical notes indicate that the service is required for: (i) pre-operative assessment; or (ii) post-exposure to blood or other body fluids assessment; or (iii) assessment before blood or tissue donation. (3) Item 69481 applies to a service in relation to a patient who displays 1 or more of the characteristics of acute or chronic hepatitis.
12 Tests in Group P4 (Immunology) relating to antibodies For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if: (a) tests are carried out in relation to a patient episode; and (b) specimen material from the patient episode is stored; and (c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material; the later tests and the earlier tests are taken to be part of 1 patient episode.
13 Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology) (1) For items in Group P5 (Tissue pathology): biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner: (a) from a medical procedure, or group of medical procedures, performed on a patient at the same time; or (b) after being expelled spontaneously from a patient. cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate. separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken. (2) For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6. (3) For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item. (4) If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services. (5) If more than 1 histopathological examination is performed on separate specimens, of different complexity levels, from a single patient episode, only the fee for the examination having the highest specified fee is applicable to the examinations. (6) In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 5 of this table. (7) If: (a) more than 1 of the services mentioned in items 72846, 72847 and 72848; or (b) more than 1 of the services mentioned in items 73059, 73060 and 73061; are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.
14 Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances (1) For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred): approved collection centre has the same meaning as in Part IIA of the Act. institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to: (a) disadvantaged children; or (b) juvenile offenders; or (c) aged persons; or (d) chronically ill psychiatric patients; or (e) homeless persons; or (f) unemployed persons; or (g) persons suffering from alcoholism; or (h) persons addicted to drugs; or (i) physically or mentally handicapped persons; but does not include: (j) a hospital; or (k) a residential care facility; or (l) accommodation for aged persons that is attached to a residential care facility or situated within a residential care facility complex. prescribed laboratory means a laboratory operated by: (a) the Commonwealth; or (b) an authority of the Commonwealth; or (c) a State or internal Territory; or (d) an authority of a State or internal Territory; or (e) an Australian tertiary education institution. residential care facility means a facility in which residential care, within the meaning of section 41-3 of the Aged Care Act 1997, is provided. specimen collection centre has the same meaning as in Part IIA of the Act. treating practitioner has the same meaning as in paragraph 16A (1) (a) of the Act. (2) If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant item does not apply to the service if: (a) the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or (b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or (c) the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or (d) a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory. (3) An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies. (4) An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service. (5) Subject to subrule (7), if 1 item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode. (6) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred. (7) If, in respect of the same patient episode: (a) services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or (b) services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; the fee specified in the applicable item in Group P10 applies to both approved pathology practitioners. (8) If more than 1 specimen is collected from a person on the same day for the provision of pathology services: (a) in accordance with more than 1 request; and (b) in or by a single approved pathology authority; the fee specified in the applicable item in Group P10 applies once only to the services. (9) The fee specified in item 73921 applies only once in respect of a single patient episode.
15 Application of an item in Group P11 (Specimen referred) to a service excludes certain other items If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73921 in respect of the patient episode.
16 Circumstances in which an item in Group P11 (Specimen referred) does not apply (1) An item in Group P11 does not apply to a referral if: (a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and (b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority. (2) An approved pathology authority is related to another approved pathology authority for subrule (1) if: (a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or (b) either of the approved pathology authorities is employed (including employed under contract) by the other; or (c) both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act 2001; or (d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or (e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or (f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory. (3) An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66515, 66536, 66596, 69300, 69303, 69333 or 73527.
17 Abbreviations (1) The abbreviations in Part 4 may be used to identify particular pathology services or groups of pathology services. (2) The names of services or drugs not listed in Part 4 must be written in full.
18 Certain pathology services to be treated as 1 service (1) In this rule: general practitioner means a medical practitioner who: (a) is not a consultant physician in any specialty; and (b) is not a specialist in any specialty. set of pathology services means a group of pathology services: (a) that consists of services that are described in at least 4 different items; and (b) all of which are requested in a single patient episode; and (c) each of which relates to a patient who is not an admitted patient of a hospital; and (d) none of which is referred to: (i) in item 66713, 66737, 66809, 66818, 69402, 69484, 73053 or 73055; or (ii) in an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred) or Group P12 (Management of bulk-billed services). (2) If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule. (3) If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set: (a) the pathology service described in the first-mentioned item is to be treated as 1 pathology service; and (b) either: (i) the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as 1 pathology service; or (ii) if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as 1 pathology service; and (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service. (4) If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set: (a) the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and (b) the pathology service in the set that is described in the item that specifies the highest fee, and has the second-lowest item number, is to be treated as 1 pathology service; and (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service. (5) If pathology services are to be treated as 1 pathology service under paragraph (3) (c) or (4) (c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1 pathology service.
19 Hepatitis C viral RNA testing For item 69444: Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive. serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.
20 Haemochromatosis testing For item 66794: elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.
21 Serum B12 and red cell folate testing (1) Items 66599 and 66602 do not apply to more than 3 patient episodes that include a service described in item 66599 or 66602, or any combination of those items, in a 12 month period. (2) Item 66599 does not apply to a service described in that item if the service was provided as part of the same patient episode as a service described in item 66602.
22 Nutritional and toxicity metals testing (1) For this rule: metal toxicity testing group means items 66672 and 66673. nutritional metals testing group means items 66669 and 66670. (2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of: (a) that item; or (b) the other item in the same group; or (c) an item in the other group.
23 Antineutrophil cytoplasmic antibody tests For subsection 16A (3) of the Act, a request for an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if: (a) the immunofluorescence test performed as a result of the request is abnormal; or (b) a previous immunofluorescence test was abnormal; or (c) those antibodies have been previously detected.
24 Satisfying requirements described in pathology service Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 3 is satisfied if: (a) in the case of a requirement for information, the information: (i) is included in the request for the service; or (ii) was supplied in writing on an earlier occasion to the approved pathology authority that rendered the service, and has been kept by the approved pathology authority; or (b) in the case of a requirement for laboratory test results, the results are: (i) included in the request for the service; or (ii) obtained from another laboratory test performed in the same patient episode; or (iii) included in results from an earlier laboratory test that have been kept by the approved pathology authority.
25 Limitation on certain items (1) For any particular patient, items 66539, 69442, 71075, 71127, 71135 and 71137 are applicable not more than twice in a 12 month period. (2) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period. (3) For any particular patient, items 66655, 66659, 69443 and 69444 are applicable not more than once in a 12 month period. (4) For any particular patient, item 66750 is applicable not more than once in a pregnancy. (5) For any particular patient, item 69336 is applicable not more than once in each period of 7 days. (6) For any particular patient, items 69445, 71079 and 73523 are applicable not more than 4 times in a 12 month period. (7) For any particular patient, item 71077 is applicable not more than 6 times in a 12 month period. (8) For any particular patient, item 69486 is applicable not more than twice in a 24 month period.
26 Antigen detection If a pathology service described in item 69364 or 69365 is a pathologist-determinable service, the amount specified in the item is not payable for the service unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service.
Part 3 Services and fees
Item
Pathology service
Fee ($)
Group P1 — Haematology
65060
Haemoglobin, erythrocyte sedimentation rate, blood viscosity — 1 or more tests
7.95
65066
Examination of: (a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or (b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha-naphthyl acetate esterase or chloroacetate esterase; or (c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or (d) a urinary sediment for haemosiderin; including a service described in item 65072
10.55
65070
Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested) — 1 or more instrument-generated set of results from a single sample and (if performed): (a) a morphological assessment of a blood film; and (b) any service in item 65060 or 65072
17.20
65072
Examination for reticulocytes including a reticulocyte count by any method — 1 or more tests
10.30
65075
Haemolysis or metabolic enzymes — assessment by 1 or more of the following tests: (a) erythrocyte autohaemolysis test; (b) erythrocyte osmotic fragility test; (c) sugar water test; (d) G-6-P D (qualitative or quantitative) test; (e) pyruvate kinase (qualitative or quantitative) test; (f) acid haemolysis test;
52.90
(g) quantitation of muramidase in serum or urine; (h) Donath Landsteiner antibody test; (i) other erythrocyte metabolic enzyme tests
65078
Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of: (a) examination for HbH; or (b) quantitation of HbA2; or (c) quantitation of HbF; including (if performed) any service described in item 65060 or 65070
91.75
65081
Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of: (a) heat denaturation test; or (b) isopropanol precipitation test; or (c) tests for the presence of haemoglobin S; or (d) quantitation of any haemoglobin fraction (including S, C, D, E); including (if performed) any service described in item 65060, 65070 or 65078
98.25
65084
Bone marrow trephine biopsy — histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunohistochemical techniques (if any); and (b) any test described in item 65060, 65066 or 65070
168.75
65087
Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunohistochemical techniques (if any); and (b) any test described in item 65060, 65066 or 65070
84.55
65090
Blood grouping (including back-grouping if performed) — ABO and Rh (D antigen)
11.25
65093
Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including item 65090 (if performed)
22.35
65096
Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of any antibodies detected; and (b) (if performed) any test described in item 65060 or 65070
41.65
65099
Compatibility tests by crossmatch — all tests performed on any one day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5)
113.40
65102
Compatibility tests by crossmatch — all tests performed on any one day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5)
170.10
65105
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5)
113.40
65108
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5)
170.10
65111
Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)
23.60
65114
1 or more of the following tests: (a) direct Coombs (antiglobulin) test; (b) qualitative or quantitative test for cold agglutinins or heterophil antibodies
9.25
65117
1 or more of the following tests: (a) spectroscopic examination of blood for chemically altered haemoglobins; (b) detection of methaemalbumin (Schumm’s test)
20.60
65120
Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D-dimer — 1 test
14.05
65123
2 tests described in item 65120
20.60
65126
3 tests described in item 65120
28.35
65129
4 or more tests described in item 65120
36.10
65132
Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism — quantitation by 1 or more techniques — 1 test
25.75
65133
2 tests described in item 65132
49.50
65134
3 tests described in item 65132
73.20
65135
4 tests described in item 65132
96.90
65136
5 tests described in item 65132
120.65
65137
Test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65132, 65133, 65134, 65135 or 65136 applies
25.75
65142
Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65132, by testing a specimen collected on a different day — 1 or more tests
25.75
65144
Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs — 1 or more tests
57.55
65147
Quantitation of anti-Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid — 1 test
38.55
65150
Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay — 1 test
72.15
65153
2 tests described in item 65150
144.35
65156
3 or more tests described in item 65150
216.50
65159
Quantitation of circulating coagulation factor inhibitors by Bethesda assay — 1 test
72.15
65162
Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)
10.55
65165
Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162
35.05
65168
Characterisation of the genotype of a patient for factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism — 1 or more tests
37.10
65171
Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item — 1 or more tests
25.75
65174
Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item 65168 — 1 or more tests
37.10
65200
Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia; each test to a maximum of 4 tests in a 12 month period
235.00
Group P2 — Chemical
66500
Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total cholesterol, total protein, triglycerides, urate or urea — 1 test
9.75
66503
2 tests described in item 66500
11.75
66506
3 tests described in item 66500
13.75
66509
4 tests described in item 66500
15.75
66512
5 tests described in item 66500
17.80
66515
6 or more tests described in item 66500
19.80
66518
Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood — tests performed on only 1 specimen in a 24 hour period
20.40
66519
Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood — tests performed on 2 or more specimens in a 24 hour period
40.85
66536
Quantitation of HDL cholesterol
11.25
66539
Electrophoresis of serum for demonstration of lipoprotein subclasses: (a) if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L; or (b) in the diagnosis of types III and IV hyperlipidaemia (Item is subject to rule 25)
31.15
66542
Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes: (a) administration of glucose; and (b) at least 2 measurements of blood glucose; and (c) (if performed) any test described in item 66695
19.30
66545
Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes: (a) administration of glucose; and (b) 1 or 2 measurements of blood glucose; and (c) (if performed) any test in item 66695
16.10
66548
Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes: (a) administration of glucose; and (b) at least 3 measurements of blood glucose; and (c) (if performed) any test in item 66695
20.30
66551
Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period
17.10
66554
Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant — each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)
17.10
66557
Quantitation of fructosamine performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period
9.85
66560
Microalbumin — quantitation in urine
20.50
66563
Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests
25.10
66566
Quantitation of: (a) blood gases (including pO2, oxygen saturation and pCO2); and
34.30
(b) bicarbonate and pH; including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen — 1 or more tests on 1 specimen
66569
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day
43.35
66572
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day
52.45
66575
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day
61.50
66578
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day
70.55
66581
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day
79.65
66584
Quantitation of ionised calcium (except if performed as part of item 66566) — 1 test
9.85
66587
Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen
48.35
66590
Calculus, analysis of 1 or more
31.15
66593
Ferritin — quantitation, except if requested as part of iron studies
18.35
66596
Iron studies, consisting of quantitation of: (a) serum iron; and (b) transferrin or iron binding capacity; and (c) ferritin
33.10
66599
Serum B12 or red cell folate and, if required, serum folate (Item is subject to rule 21)
24.05
66602
Serum B12 and red cell folate and, if required, serum folate (Item is subject to rule 21)
43.75
66605
Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid — 1 or more tests within a 6 month period
31.15
66608
Vitamin D or D fractions — 1 or more tests
43.00
66623
All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program
42.25
66626
Detection or quantitation or both of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program, including all tests on blood, urine or other body fluid, not including: (a) the surveillance of sports people and athletes for performance improving substances; and (b) the detection of nicotine and metabolites in smoking withdrawal programs (Item is subject to rule 25)
24.55
66629
Beta-2-microglobulin — quantitation in serum, urine or other body fluids — 1 or more tests
20.50
66632
Caeruloplasmin, haptoglobins, or prealbumin — quantitation in serum, urine or other body fluids — 1 or more tests
20.50
66635
Alpha-1-antitrypsin — quantitation in serum, urine or other body fluid — 1 or more tests
20.50
66638
Isoelectric focussing or similar methods for determination of alpha-1-antitrypsin phenotype in serum — 1 or more tests
29.70
66641
Electrophoresis of serum or other body fluid to demonstrate: (a) the isoenzymes of lactate dehydrogenase; or (b) the isoenzymes of alkaline phosphatase; including the preliminary quantitation of total relevant enzyme activity — 1 or more tests
29.70
66644
C-1 esterase inhibitor — quantitation
20.50
66647
C-1 esterase inhibitor — functional assay
45.90
66650
Alpha-fetoprotein, CA-15.3 antigen (CA15.3), CA-19.9 antigen (CA19.9), CA-125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour — quantitation — 1 test
24.75
66653
2 or more tests described in item 66650
45.35
66655
Prostate specific antigen (PSA) quantitation (Item is subject to rule 25)
20.50
66656
Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item 66655 applies)
20.50
66659
Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies in the equivocal range of the particular method of assay used to determine the level (Item is subject to rule 25)
37.80
66662
Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests
81.35
66665
Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test
31.15
66667
Quantitation of serum zinc in a patient receiving intravenous alimentation — each test
31.15
66669
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 1 test (Item is subject to rule 22)
31.15
66670
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 2 or more tests in relation to the same patient (Item is subject to rule 22)
53.35
66671
Quantitation of serum aluminium in a patient in a renal dialysis program — each test
37.55
66672
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 1 test (Item is subject to rule 22)
31.15
66673
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 2 or more tests in relation to the same patient (Item is subject to rule 22)
53.35
66674
Quantitation of: (a) faecal fat; or (b) breath hydrogen in response to loading with disaccharides; 1 or more tests within a 28 day period
40.65
66677
Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old
11.35
66680
Quantitation of disaccharidases and other enzymes in intestinal tissue — 1 or more tests
75.75
66683
Enzymes — quantitation in solid tissue or tissues other than blood elements or intestinal tissue — 1 or more tests
75.75
66686
Performance of 1 or more of the following procedures: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) sweat collection by iontophoresis for chloride analysis; (e) pharmacological stimulation of growth hormone
51.55
66695
Quantitation in blood or urine of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF –1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test
30.70
66698
2 tests described in item 66695 (Item is subject to rule 6)
43.80
66701
3 tests described in item 66695 (Item is subject to rule 6)
57.20
66704
4 tests described in item 66695 (Item is subject to rule 6)
70.60
66707
5 tests described in item 66695 (Item is subject to rule 6)
84.05
66710
6 or more tests described in item 66695 (Item is subject to rule 6)
97.45
66711
Quantitation in saliva of cortisol in: (a) the investigation of Cushing’s syndrome; or (b) the management of children with congenital adrenal hyperplasia
30.70
66712
Quantitation in saliva of cortisol as described in item 66711 performed on 2 specimens on any 1 day
43.80
66713
Tests described in item 66695, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)
13.40
66716
TSH quantitation
25.45
66719
Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied: (a) the patient has an abnormal level of TSH;
35.45
(b) the tests are performed: (i) for the purpose of monitoring thyroid disease in the patient; or (ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or (iii) to investigate dementia or psychiatric illness of the patient; or (iv) to investigate amenorrhoea or infertility of the patient;
(c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction; (d) the patient is on drugs that interfere with thyroid hormone metabolism or function (Item is subject to rule 9)
66722
TSH quantitation described in item 66716 and 1 test described in item 66695 (Item is subject to rule 6)
38.55
66725
TSH quantitation described in item 66716 and 2 tests described in item 66695 (Item is subject to rule 6)
51.95
66728
TSH quantitation described in item 66716 and 3 tests described in item 66695 (Item is subject to rule 6)
65.35
66731
TSH quantitation described in item 66716 and 4 tests described in item 66695 (Item is subject to rule 6)
78.75
66734
TSH quantitation described in item 66716 and 5 tests described in item 66695 (Item is subject to rule 6)
92.15
66737
Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)
13.40
66743
Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751
20.50
66749
Amniotic fluid, spectrophotometric examination of, and quantitation of: (a) lecithin/sphingomyelin ratio; or (b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or
33.50
(c) bilirubin, including correction for haemoglobin; 1 or more tests
66750
Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality: (a) total human chorionic gonadotrophin (total HCG); (b) free alpha human chorionic gonadotrophin (free alpha HCG); (c) free beta human chorionic gonadotrophin (free beta HCG); (d) pregnancy associated plasma protein A (PAPP-A);
40.45
(e) unconjugated oestriol (uE3); (f) alpha-fetoprotein (AFP); including (if performed) a service described in item 73527 or 73529 (Item is subject to rule 25)
66751
Quantitation, in pregnancy, of any 3 or more tests described in item 66750
56.20
66752
Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776) — 1 test
25.10
66755
2 or more tests described in item 66752
39.50
66758
Quantitation of angiotensin converting enzyme, or cholinesterase — 1 or more tests
25.10
66761
Test for reducing substances in faeces by any method (except reagent strip or dipstick)
13.40
66764
Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by: (a) an immunological method; and
9.05
(b) a chemical method (except reagent strip or dip stick); with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods
66767
2 examinations by both methods described in item 66764 performed on separately collected and identified specimens
18.15
66770
3 examinations by both methods described in item 66764 performed on separately collected and identified specimens
27.20
66773
Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density and, if performed, a service described in item 66752 — 1 or more tests
25.10
66776
Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget’s disease of bone and, if performed, a service described in item 66752 — 1 or more tests
25.10
66779
Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin — quantitation — 1 or more tests
40.65
66782
Porphyrins or porphyrins precursors — detection in plasma, red cells, urine or faeces — 1 or more tests
13.40
66785
Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 1 test
40.65
66788
Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 2 or more tests
67.00
66791
Porphyrin biosynthetic enzymes — measurement of activity in blood cells or other tissues — 1 or more tests
75.75
66794
Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)
37.10
66800
Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin — 1 test (Item is subject to rule 6)
18.45
66803
2 tests described in item 66800 (Item is subject to rule 6)
31.05
66806
3 tests described in item 66800 (Item is subject to rule 6)
43.60
66809
Tests described in item 66800, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 2 tests
12.60
66812
Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test (Item is subject to rule 6)
35.45
66815
2 tests described in item 66812 (Item is subject to rule 6)
60.60
66818
Tests described in item 66812, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 1 test (Item is subject to rule 6)
25.15
Group P3 — Microbiology
69300
Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including (if performed): (a) differential cell count; or (b) examination for dermatophytes; or (c) dark ground illumination; or (d) stained preparation or preparations using any relevant stain or stains; 1 or more tests
12.60
69303
Culture and (if performed) microscopy to detect pathogenic micro-organisms from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300; specimens from 1 or more sites
22.15
69306
Microscopy and culture to detect pathogenic micro-organisms from skin or other superficial sites, including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69312 and 69318; 1 or more tests on 1 or more specimens
34.00
69309
Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed): (a) the detection of antigens not elsewhere specified in this table; or (b) a service described in items 69300, 69303, 69306, 69312 and 69318; 1 or more tests on 1 or more specimens
48.45
69312
Microscopy and culture to detect pathogenic micro-organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69306 and 69318; 1 or more tests on 1 or more specimens
34.00
69318
Microscopy and culture to detect pathogenic micro-organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or
34.00
(b) a service described in items 69300, 69303, 69306 and 69312; 1 or more tests on 1 or more specimens
69321
Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites
48.45
69324
Microscopy (with appropriate stains) and culture for mycobacteria — 1 specimen of sputum, urine or other body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service mentioned in item 69300
43.30
69327
Microscopy (with appropriate stains) and culture for mycobacteria — 2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300
85.55
69330
Microscopy (with appropriate stains) and culture for mycobacteria — 3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300
128.85
69333
Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count; and (d) (if performed) identification of cultured pathogens; and
20.70
(e) (if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts
69336
Microscopy of faeces for ova, cysts and parasites, that includes the use of: (a) a concentration technique; and (b) fixed stains or antigen detection for cryptosporidia and giardia; and includes a service mentioned in item 69300 (if performed) (Item is subject to rule 25)
33.65
69339
Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336 — not more than 1 examination in a 7 day period
19.25
69345
Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed): (a) pathogen identification and antibiotic susceptibility testing; and (b) the detection of clostridial toxins; and (c) a service described in item 69300 Not more than 1 examination in a 7 day period
53.25
69354
Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed): (a) identification of any cultured pathogen; and (b) necessary antibiotic susceptibility testing; to a maximum of 3 sets of cultures — 1 set of cultures
30.95
69357
2 sets of cultures described in item 69354
61.85
69360
3 sets of cultures described in item 69354
92.80
69363
Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345 has been performed) — 1 or more tests
28.85
69364
Detection of a virus, microbial antigen or microbial nucleic acid (not elsewhere described in this table) — 1 test (Item is subject to rule 26)
28.85
69365
2 or more tests described in item 69364 (Item is subject to rule 26)
36.10
69378
Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy — 1 or more tests on 1 or more specimens
181.45
69381
Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient on antiretroviral therapy — 1 or more tests on 1 or more specimens
181.45
69382
Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero-positive patient — 1 or more tests on 1 or more specimens
181.45
69384
Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in this table — 1 test (Item is subject to rule 6)
15.75
69387
2 tests described in item 69384 (Item is subject to rule 6)
28.85
69390
3 tests described in item 69384 (Item is subject to rule 6)
43.30
69393
4 tests described in item 69384 (Item is subject to rule 6)
57.75
69396
5 tests described in item 69384 (Item is subject to rule 6)
72.15
69399
6 or more tests described in item 69384
86.60
69402
Tests described in item 69384, if rendered under a request referred to in subparagraph 6 (2) (a) (iii) of Part 2 — each test to a maximum of 5 tests (Item is subject to rule 6)
14.45
69405
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 1 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481
15.75
69408
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 2 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481
28.00
69411
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 3 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481
39.35
69413
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 4 of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481
50.65
69415
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of all of the following — rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481
61.95
69442
Quantitation of HCV RNA load in plasma or serum in: (a) the pre-treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or (b) the assessment of efficacy of antiviral therapy for such a patient; if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69444 or 69445) (Item is subject to rule 25)
181.45
69443
Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if: (a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and
206.20
(b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient
(Item is subject to rule 25)
69444
Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied: (a) the patient is Hepatitis C sero-positive; (b) the patient’s serological status is uncertain after testing; (c) the test is performed for the purpose of: (i) determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or
92.80
(ii) the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient (Item is subject to rules 19 and 25)
69445
Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69444) — 1 test (Item is subject to rule 25)
92.80
69471
Test of cell-mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient — 1 test
35.15
69472
Detection of antibodies to Epstein Barr Virus using specific serology — 1 test
15.75
69474
Detection of antibodies to Epstein Barr Virus using specific serology — 2 or more tests
28.85
69475
Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 1 test, including: (a) Hepatitis A antibody test; or
15.75
(b) Hepatitis B antibody or antigen test; or (c) Hepatitis C antibody test; or (d) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)
69478
Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D — 2 tests, including: (a) Hepatitis A antibody test; or (b) Hepatitis B surface or core antibody test; or (c) Hepatitis B surface antigen test; or (d) Hepatitis B ‘e’ antibody or ‘e’ antigen test; or (e) Hepatitis C antibody test; or (f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)
29.45
69481
Investigation of infectious causes of acute or chronic hepatitis — 3 tests, including: (a) Hepatitis A antibody test; or (b) Hepatitis B core antibody test; or (c) Hepatitis B ‘e’ antibody or ‘e’ antigen test; or (d) Hepatitis B surface antibody or surface antigen test; or (e) Hepatitis C antibody test; or (f) Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive (Item is subject to rule 11)
40.80
69484
Supplementary test for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing
17.20
69486
A test for high risk human papillomaviruses (HPV) in a patient who, within the 2 year period before the test: (a) has received excisional or ablative treatment for high grade intraepithelial abnormalities of the cervix; or (b) has had a positive HPV test after excisional or ablative treatment for high grade intraepithelial abnormalities of the cervix (Item is subject to rule 25)
64.00
Group P4 — Immunology
71057
Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; including the preliminary quantitation of total protein, albumin and globulin — 1 specimen type
36.30
71058
Examination as described in item 71057 of 2 or more specimen types
51.40
71059
Electrophoresis and immunofixation, immunoelectrophoresis or isoelectric focussing of: (a) urine for detection of Bence Jones proteins; or (b) serum, plasma or other body fluid; and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised — examination of 1 specimen type (eg serum, urine or CSF)
29.70
71060
Examination as described in item 71059 of 2 or more specimen types
44.80
71062
Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes — 1 or more tests
44.80
71064
Detection and quantitation of cryoglobulins or cryofibrinogen — 1 or more tests
21.10
71066
Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid — 1 test
14.80
71068
Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid — 1 test
14.80
71069
2 tests described in item 71066, 71068, 71072 or 71074
23.15
71071
3 or more tests described in item 71066, 71068, 71072 or 71074
31.50
71072
Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid — 1 test
14.80
71073
Quantitation of all 4 immunoglobulin G subclasses
108.00
71074
Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid — 1 test
14.80
71075
Quantitation of immunoglobulin E (total) — 1 test (Item is subject to rule 25)
23.40
71077
Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis — 1 test (Item is subject to rule 25)
27.55
71079
Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens (Item is subject to rule 25)
27.30
71081
Quantitation of total haemolytic complement
41.25
71083
Quantitation of complement components C3 and C4 or properdin factor B — 1 test
20.50
71085
2 tests described in item 71083
29.45
71087
3 or more tests described in item 71083
38.35
71089
Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table — 1 test
29.65
71091
2 tests described in item 71089
53.70
71093
3 or more tests described in item 71089
77.80
71095
Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years
41.25
71097
Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required
24.85
71099
Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method
27.00
71101
Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids
17.70
71103
Characterisation of an antibody detected in a service described in item 71101 (including that service)
52.95
71106
Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required
11.50
71109
Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody
35.15
71113
Detection of 2 antibodies described in item 71109
48.25
71115
Detection of 3 antibodies described in item 71109
61.35
71117
Detection of 4 or more antibodies described in item 71109
74.45
71119
Antibodies to tissue antigens not elsewhere specified in this table — detection, including quantitation if required, of 1 antibody
17.65
71121
Detection of 2 antibodies specified in item 71119
21.15
71123
Detection of 3 antibodies specified in item 71119
24.65
71125
Detection of 4 or more antibodies specified in item 71119
28.15
71127
Functional tests for lymphocytes — quantitation, other than by microscopy, of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or
179.45
(c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65066 or 65070 (if performed) (Item is subject to rule 25)
71129
2 tests described in item 71127
221.65
71131
3 or more tests described in item 71127
263.90
71133
Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test
10.55
71134
Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)
105.85
71135
Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in item 65066, 65070, 71133 or 71134 (if performed) (Item is subject to rule 25)
211.60
71137
Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens (Item is subject to rule 25)
30.80
71139
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid
105.85
71141
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens
200.85
71143
Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue
264.55
71145
Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid
431.95
71146
Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count
105.85
71147
HLA-B27 typing
41.25
71149
Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147
110.15
71151
Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens
120.95
71153
Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests: (a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test; (b) antineutrophil proteinase 3 antibody (PR3 ANCA) test; (c) antimyeloperoxidase antibody (MPO ANCA) test; (d) antiglomerular basement membrane antibody (GBM ANCA) test (Item is subject to rule 23)
35.15
71155
Testing for the presence of 2 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)
48.25
71157
Testing for the presence of 3 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)
61.35
71159
Testing for the presence of 4 antibodies by tests mentioned in item 71153 (Item is subject to rule 23)
74.45
71163
Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed): (a) antibodies to gliadin; (b) antibodies to endomysium; (c) antibodies to tissue transglutaminase 1 test
25.15
71164
2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed)
40.60
Group P5 — Tissue pathology
72813
Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)
72.15
72816
Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen (Item is subject to rule 13)
87.10
72817
Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens (Item is subject to rule 13)
97.45
72818
Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 or more separately identified specimens (Item is subject to rule 13)
107.75
72823
Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen (Item is subject to rule 13)
97.95
72824
Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens (Item is subject to rule 13)
142.30
72825
Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 to 7 separately identified specimens (Item is subject to rule 13)
181.45
72826
Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 8 or more separately identified specimens (Item is subject to rule 13)
195.90
72830
Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)
190.75
72836
Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens (Item is subject to rule 13)
293.85
72844
Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system — 1 or more tests
30.95
72846
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 72848 (Item is subject to rule 13)
43.30
72847
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies (Item is subject to rule 13)
57.75
72848
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies: (a) oestrogen; (b) progesterone; (c) c-erb-B2 (HER2) (Item is subject to rule 13)
51.55
72851
Electron microscopic examination of biopsy material — 1 separately identified specimen (Item is subject to rule 13)
185.60
72852
Electron microscopic examination of biopsy material — 2 or more separately identified specimens (Item is subject to rule 13)
247.45
72855
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 1 separately identified specimen (Item is subject to rule 13)
185.60
72856
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 2 to 4 separately identified specimens (Item is subject to rule 13)
247.45
72857
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear — 5 or more separately identified specimens (Item is subject to rule 13)
288.70
Group P6 — Cytology
73043
Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests
23.00
73045
Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), 1 or more tests on: (a) specimens resulting from washings or brushings from sites not specified in item 73043; or (b) a single specimen of sputum or urine; or (c) 1 or more specimens of other body fluids
48.95
73047
Cytology of a series of 3 sputum or urine specimens for malignant cells
95.35
73049
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues
69.60
73051
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if: (a) the aspiration is performed by a recognised pathologist; or (b) a recognised pathologist attends the aspiration and performs a cytological examination during the attendance
171.50
73053
Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each examination: (a) for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or (b) if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph (a); or (c) if there is inadequate information provided to use item 73055
19.60
73055
Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test: (a) for the management of previously detected abnormalities including precancerous or cancerous conditions; or (b) for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia
19.60
73057
Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist — each test
19.60
73059
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies except those mentioned in item 73061 (Item is subject to rule 13)
43.30
73060
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies (Item is subject to rule 13)
57.75
73061
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 of the following antibodies:
(a) oestrogen;
(b) progesterone;
(c) c-erb-B2 (HER2)
(Item is subject to rule 13)
51.55
Group P7 — Genetics
73287
Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of 1 or more of any tissue or fluid except blood — 1 or more tests
401.45
73289
Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of blood — 1 or more tests
365.20
73300
Detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where: (a) the patient exhibits 1 or more of the clinical features of fragile X (A) syndrome, including intellectual disabilities; or (b) the patient has a relative with a fragile X (A) mutation 1 or more tests
103.10
73305
Detection of genetic mutation of the FMR1 gene by Southern Blot, if the results of a service performed in item 73300 are inconclusive
206.20
Group P8 — Infertility and pregnancy tests
73521
Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)
9.80
73523
Semen examination (other than post-vasectomy semen examination), including: (a) measurement of volume, sperm count and motility; and (b) examination of stained preparations; and (c) morphology; and (d) (if performed) differential count and 1 or more chemical tests (Item is subject to rule 25)
42.50
73525
Sperm antibodies — sperm-penetrating ability — 1 or more tests
28.85
73527
Human chorionic gonadotrophin (HCG) — detection in serum or urine by 1 or more methods for diagnosis of pregnancy — 1 or more tests
10.20
73529
Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527 — 1 test
29.15
Group P9 — Simple basic pathology tests
73801
Semen examination for presence of spermatozoa
6.95
73802
Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test
4.60
73803
2 tests described in item 73802
6.40
73804
3 or more tests described in item 73802
8.20
73805
Microscopy of urine, whether stained or not, or catalase test
4.60
73806
Pregnancy test by 1 or more immunochemical methods
10.20
73807
Microscopy for wet film other than urine, including any relevant stain
6.95
73808
Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807
8.70
73809
Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method
2.35
73810
Microscopy for fungi in skin, hair or nails — 1 or more sites
6.95
73811
Mantoux test
11.30
Group P10 — Patient episode initiation
73901
Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory
8.25
73903
Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital
14.75
73905
Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital
8.25
73907
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected: (a) until 30 November 2001 — in a licensed collection centre (within the meaning of Part IIA of the Act); or (b) after that date — in an approved collection centre
17.40
73909
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital
17.70
73910
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing
10.30
73912
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential care facility or institution
17.70
73913
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905, 73907 or items in Group P9) if the specimen is collected from the person by the person
9.80
73915
Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner
9.80
Group P11 — Specimen referred
73921
Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority (Item is subject to rules 14, 15 and 16)
10.30
Group P12 — Management of bulk-billed services
74990
A pathology service to which an item in this table (other than this item or item 74991) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital or day-hospital facility; and (d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service
5.85
74991
A pathology service to which an item in this table (other than this item or item 74990) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital or day-hospital facility; and
8.80
(d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service; and
(e) the service is provided at, or from, a practice location in: (i) a regional, rural or remote area; or (ii) Tasmania; or (iii) a geographical area included in any of the following SSD spatial units: (A) Beaudesert Shire Part A; (B) Belconnen;
(C) Darwin City; (D) Eastern Outer Melbourne; (E) East Metropolitan; (F) Frankston City;
(G) Gosford-Wyong; (H) Greater Geelong City Part A; (I) Gungahlin-Hall; (J) Ipswich City (Part in BSD); (K) Litchfield Shire; (L) Melton-Wyndham; (M) Mornington Peninsula Shire; (N) Newcastle; (O) North Canberra; (P) Palmerston-East Arm; (Q) Pine Rivers Shire; (R) Queanbeyan;
(S) South Canberra; (T) South Eastern Outer Melbourne; (U) Southern Adelaide; (V) South West Metropolitan; (W) Thuringowa City Part A; (X) Townsville City Part A; (Y) Tuggeranong; (Z) Weston Creek-Stromlo; (ZA) Woden Valley; (ZB) Yarra Ranges Shire Part A; or (iv) the geographical area included in the SLA spatial unit of Palm Island (AC)
Part 4 Abbreviations Note A drug that is not mentioned in this Part must be written in full.
Test
Abbreviation
Item
Abnormal haemoglobins
AH
65117
Acetoacetate
ACAT
66500
Acetylcholine receptor — tissue antigens — antibodies
ARA
71109
Acid phosphatase
ACP
66500
Actinomycetes — microbial antibody testing
ACT
69384
Activated Protein C resistance
APC
65132–36, 65142, 65171
Adenovirus — microbial antibody testing
ADE
69384
Adrenal cortex — tissue antigens — antibodies
ADR
71109
Adrenocorticotrophic hormone (ACTH)
ACTH
66695
AFB microscopy and culture of sputum — 1 specimen
AFB1
69324
AFB microscopy and culture of sputum — 2 specimens
AFB2
69327
AFB microscopy and culture of sputum — 3 specimens
AFB3
69330
Alanine aminotransferase
ALT
66500
Albumin
ALB
66500
Alcohol (ethanol)
ETOH
66626, 66800
Aldosterone
ALDS
66695
Alkaline phosphatase
ALP
66500
Alkaline phosphatase — isoenzymes
ALPI
66641
Alpha-1-antitrypsin
AAT
66635
Alpha-fetoprotein
AFP
66650–53, 66743, 66750, 66751
Aluminium
AL
66672–73
Aluminium — renal dialysis
ALR
66671
Amikacin
66800
Amino acids
AA
66752
Amiodarone
AMIO
66812
Amitriptyline
AMIT
66812
Ammonia
NH3
66500
Amniotic fluid examination
AFE
66749
Amylase
AMS
66500
Amylobarbitone
AMYL
66812
Androstenedione
ANDR
66695
Angiotensin converting enzyme
ACE
66758
Antibiotic and antimicrobial chemotherapeutic agents — quantitation
QAA
66800, 66812
Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA
ENAP
71103
Antibodies to extractable nuclear antigens — detection
ENA
71101
Antibodies to nuclear antigens — detection
ANA
71097
Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA
ANAP
71099
Antibodies to tissue antigens — acetylcholine receptor
ARA
71109
Antibodies to tissue antigens — adrenal cortex
ADR
71109
Antibodies to tissue antigens — ANCA- myeloperoxidase
MPO
71153
Antibodies to tissue antigens — ANCA-PR3
PR3
71153
Antibodies to tissue antigens — anti-actin
AACT
71119
Antibodies to tissue antigens — anti-endomysial
EMA
71163
Antibodies to tissue antigens — cardiolipin
ACL
71109
Antibodies to tissue antigens — coeliac disease panel
CLC
71163–64
Antibodies to tissue antigens — gastric parietal cell
PCA
71119
Antibodies to tissue antigens — gliadin IgA
GLIA
71163
Antibodies to tissue antigens — gliadin IgG
GLIG
71163
Antibodies to tissue antigens — glomerular basement membrane
GBM
71153
Antibodies to tissue antigens — heart
AHE
71109
Antibodies to tissue antigens — histone
AHI
71109
Antibodies to tissue antigens — insulin receptor antibodies
INSA
71109
Antibodies to tissue antigens — intercellular cement substance of skin
ICCS
71109
Antibodies to tissue antigens — intrinsic factor
AIF
71109
Antibodies to tissue antigens — islet cell
AIC
71109
Antibodies to tissue antigens — Jo-1
JO1
71119
Antibodies to tissue antigens — keratin
KERA
71119
Antibodies to tissue antigens — liver/kidney microsomes
LKA
71119
Antibodies to tissue antigens — lymphocyte
ALY
71109
Antibodies to tissue antigens — mitochondria
MA
71119
Antibodies to tissue antigens — neuron
ANE
71109
Antibodies to tissue antigens — neutrophil cytoplasm
ANCA
71153
Antibodies to tissue antigens — ovary
AOV
71109
Antibodies to tissue antigens — parathyroid
PTHA
71109
Antibodies to tissue antigens — platelet
APA
71109
Antibodies to tissue antigens — PM-Sc1
PM1
71119
Antibodies to tissue antigens — reticulin
RCA
71119
Antibodies to tissue antigens — salivary gland
ASG
71109
Antibodies to tissue antigens — Scl-70
SCL
71119
Antibodies to tissue antigens — skeletal muscle
SLA
71109
Antibodies to tissue antigens — skin basement membrane
SKA
71109
Antibodies to tissue antigens — smooth muscle
SMA
71119
Antibodies to tissue antigens — thyroglobulin
ATG
71109
Antibodies to tissue antigens — thyroid microsome
TMA
71109
Antibodies to tissue antigens — tissue transglutaminase
TTG
71163
Antibodies to tissue antigens — TSH receptor antibody test
TSHA
71109
Antibody testing, microbial (see Microbial)
Antigen testing, microbial (see Microbial)
Antithrombin III
ATH
65132–36, 65142, 65171
Anti-Xa activity
QAXA
65147
Anus — cytology on specimens from
SMCY
73043
Apolipoprotein B/A1 ratio
APO
66536
Arsenic
AS
66672–73
Aspartate aminotransferase
AST
66500
Aspergillus — microbial antibody testing
ASP
69384
Avian precipitins (bird fancier’s disease) — microbial antibody testing
APP
69384
B12 vitamin
B12
66599
Barbiturate
BARB
66800, 66812
Beryllium
BE
66672–73
Beta-2-microglobulin
BMIC
66629
Beta-hydroxybutyrate
BHYB
66500
Bicarbonate
HCO3
66500
Bilirubin (all fractions)
BILI
66500
Bilirubin (all fractions) — in urine
UBIL
66500
Bilirubin (all fractions) — neonatal
BILN
66749
Bird fancier’s disease (see avian precipitins)
APP
69384
Blastomyces — microbial antibody testing
BLM
69384
Blood — compatibility testing
XMAT
65099–108
Blood — culture
BC
69354–60
Blood — faecal occult
FOB
66764–70
Blood — film
BF
65066
Blood — full examination
FBE
65070
Blood — gases
GAS
66566
Blood — group and blood group antibodies
BGAB
65096
Blood — group antibodies
BGA
65111
Blood — group systems
BGS
65093
Blood — grouping — ABO and RH (D antigen)
BG
65090
Blood — viscosity
VISC
65060
Body cavities — aspirations of — microscopy and culture of material from
MCPO
69321
Body fluids — cytology
BFCY
73045
Bone — low mineral densities
CBLB
66773
Bone — metabolic bone disease
CBMB
66776
Bone marrow examination — aspirate
BMEA
65087
Bone marrow examination — trephine
BMET
65084
Bordetella pertussis — microbial antibody testing
BOR
69384
Borrelia burgdorferi — microbial antibody testing
BOB
69384
Breath hydrogen test
BHT
66674
Bromide
BRMD
66812
Brucella — microbial antibody testing
BRU
69384
C-l esterase inhibitor — functional
CEIF
66647
C-l esterase inhibitor — quantitation
CEIQ
66644
CA-15.3 antigen
CA15
66650
CA-19.9 antigen
CA19
66650
CA-125 antigen
C125
66650
Cadmium
CD
66672–73
Caeruloplasmin
CPLS
66632
Calcitonin
CALT
66695
Calcium — ionised
ICA
66584
Calcium (total or corrected for albumin)
CA
66500
Calculus analysis
CALC
66590
Campylobacter jejuni — microbial antibody testing
CAM
69384
Candida — microbial antibody testing
CAN
69384
Carbamazepine (Tegretol)
CARB
66800
Carboxyhaemoglobin
COHB
65117
Carcinoembryonic antigen
CEA
66650
Cardiac enzymes
CE
66506
Cardiolipin — tissue antigens — antibodies
ACL
71109
Catecholamines
CAT
66779
Cell mediated immunity — delayed type — hypersensitivity test
CMI
71137
Cell-mediated immunity in blood
CMIB
69471
Cervix — cytology — abnormalities
CCRA
73055
Cervix — cytology — routine
CCR
73053
Cervix — microscopy and culture of material from
MCGR
69312
Characterisation of antibodies if positive ENA
ENAP
71103
Chemicals, toxic (ingested or absorbed) — assays
DRGO
66623
Chlamydia — investigation by any method
CHLM
69364
Chlamydia — investigation by any method and N gonorrhoea by NAA methods
CHGO
69364
Chlamydia — microbial antibody testing
CHL
69384
Chlamydia — microbial antigen testing
MCCH
69364
Chloral hydrate
CHHY
66812
Chlorazepate
CHZP
66812
Chloride
CL
66500
Chloroquine
CLOQ
66812
Chlorpromazine
CHLO
66812
Cholesterol
CHOL
66500
Cholesterol — HDL
HDLC
66536
Cholinesterase
CHSE
66758
Chorionic gonadotrophin — quantitation
HCG
66650–53, 66750, 66751, 73529
Chorionic gonadotrophin — detection for pregnancy diagnosis
HCGP
73527–29
Chromium
CR
66672–73
Chromosome identification — studies — blood
CSB
73289
Chromosome identification — studies — other than blood
CS
73287
Chromosome identification and banding
73287–89
Cimetidine
CMTD
66812
Clobazam
CLOB
66812
Clomipramine
CLOM
66812
Clonazepam (Rivotril)
CLON
66812
Clostridium difficile — microbial antigen testing
CLDT
69363
Coagulation factor inhibitors by Bethesda assay
BETH
65159
Coagulation — factors (see individual factors)
Coagulation — studies
COAG
65120
Coccidioides — microbial antibody testing
CCC
69384
Coeliac antibodies
CLC
71163–64
Cold agglutinins
CAG
65114
Collagen — low bone
CBLB
66773
Collagen — metabolic disease
CBMB
66776
Compatibility testing
XMAT
65099–108
Complement, total haemolytic
COM
71081
Complement, total haemolytic — components C3
C3
71083
Complement, total haemolytic — components C4
C4
71083
Complement, total haemolytic — other components
COMP
71089
Complement, total haemolytic — properdin factor B
PFB
71083
Copper
CU
66669–70
Cortisol
CORT
66695
Cortisol in saliva
CORS
66711–12
Coxsackie B1-6 — microbial antibody testing
COX
69384
C-Peptide
CPEP
66695
C-reactive protein
CRP
66500
Creatine kinase
CK
66500
Creatine kinase — isoenzymes
CKI
66518
Creatine kinase — isoenzymes (electrophoresis)
CKIE
66518
Creatinine
C
66500
Cryofibrinogen — detection and quantitation
CFID
71064
Cryoglobulins — characterisation by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing
RYO
71059
Cryoglobulins — detection and quantitation
CGLD
71064
Cryptococcal antigen — microbial antigen testing
CRYN
69364
Cryptococcus — microbial antibody testing
CRY
69384
CSF — microscopy and culture of material from
MCPO
69321
CSF antigens — group B streptococcus
STB
69364
CSF antigens — Haemophilus influenzae
HI
69364
CSF antigens — Neisseria meningitidis
NMG
69364
CSF antigens — Streptococcus pneumoniae
SPN
69364
Cultural examination of faeces
FCS
69345
Cyclic AMP
CAMP
66695
Cyclosporin A
CLSA
66812
Cystine — qualitative
UCYS
66752
Cystine — quantitative
CYST
66752
Cytology — fine needle aspiration of solid tissues
FNCY
73049
Cytology — fine needle aspiration of solid tissues — aspiration or attendance by a pathologist
FNCP
73051
Cytology — from 3 sputum or urine specimens
SPCY
73047
Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings
BFCY
73045
Cytology — from cervix — abnormalities
CCRA
73055
Cytology — from cervix — routine
CCR
73053
Cytology — from skin, nipple discharge, lip, mouth, nose or anus
SMCY
73043
Cytology — from vagina
CVO
73057
Cytomegalovirus — microbial antibody testing
CMV
69384
Cytomegalovirus serology in pregnancy — microbial antibody testing
CMVP
69405–11
D vitamin
VITD
66608
D-dimer test
DD
65120
Dehydroepiandrosterone sulphate (DHEAS)
DHEA
66695
Dengue — microbial antibody testing
DEN
69384
11-Deoxycortisol
DCOR
66695
Desipramine
DESI
66812
Dexamethasone
DXST
66686
Dexamethasone — suppression test
DEXA
66686
DHEAS (Dehydroepiandrosterone sulphate)
DHEA
66695
Diazepam
DIAZ
66812
Differential cell count
DIFF
65070
Digoxin
DIG
66800
Dihydrotestosterone
DHTS
66695
Diphenylhydantoin (Dilantin)
DIL
66812
Diphtheria — microbial antibody testing
DIP
69384
Direct Coombs test
CMBS
65114
Disopyramide (Rythmodan)
DISO
66800
DNA binding — quantitation and measurement if positive ANA
ANAP
71099
DNA (double-stranded DNA) antibody
DSDNA
71099
Donath Landsteiner antibody test
DLAT
65075
Down’s syndrome and neural tube defects
NTDD
66750, 66751
Doxepin hydrochloride
DOXE
66812
Drugs — abuse treatment programme — assay
DATP
66626
Drugs — inappropriate dosage — assay
DRGO
66623
Drugs — therapeutic — assay (see individual drugs)
66800, 66812
Dynamic function tests
GHSE
66686
Ear — microscopy and culture of material from
MCSW
69303
Echinococcus — microbial antibody testing
ECC
69384
Echis test
ECHI
65120
ECHO-coxsackie group — microbial antibody testing
ECH
69384
Electrolytes
E
66509
Electron microscopy of biopsy material
EM
72851–52
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of cryoglobulins
RYO
71059
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focussing — characterisation of paraprotein
PRYO
71059
Electrophoresis, to demonstrate — creatine kinase isoenzymes
CKIE
66518
Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes
LDI
66641
Electrophoresis, to demonstrate — lipoprotein subclasses
LEPG
66539
Electrophoresis, to demonstrate — quantitation of protein classes, or paraprotein
EPPI
71057–58
Elements (see individual elements)
Endomysium antibodies
EMA
71163
Entamoeba histolytica — microbial antibody testing
AMO
69384
Enzyme assays of solid tissue or tissues
ENZS
66683
Enzyme histochemistry of skeletal muscle
EHSK
72844
Eosinophil cationic protein
ECP
71095
Epstein Barr virus — microbial antibody testing
EBV
69472–74
Erythrocyte — assessment of haemolysis
ERYH
65075
Erythrocyte — assessment of metabolic enzymes
ERYM
65075
Erythrocyte — count
RCC
65070
Erythrocyte — sedimentation rate
ESR
65060
Ethanol (alcohol)
ETOH
66626, 66800
Ethosuximide (Zarontin)
ETHO
66800
Extractable nuclear antigens — detection of antibodies to
ENA
71101
Eye — microscopy and culture of material from
MCSW
69303
Factor II
FII
65150
Factor V
FV
65150
Factor V Leiden mutation
FVLM
65168, 65174
Factor VII
FVII
65150
Factor VIII
VIII
65150
Factor IX
FIX
65150
Factor X
FX
65150
Factor XI
FXI
65150
Factor XII
FXII
65150
Factor XIII
XIII
65150
Factor XIII deficiency test
F13D
65120
Faecal antigen test for Helicobacter pylori
FAHP
69364
Faecal blood
FOB
66764–70
Faecal fat
FFAT
66674
Faecal fat — haemoglobin
FFH
66764
Faecal fat — reducing substances
FRS
66761
Faeces — culture
FCS
69345
Faeces — microscopy for parasites
OCP
69336–39
Ferritin (see also Iron studies)
FERR
66593
Fibrin monomer
FM
65120
Fibrinogen
FIB
65120
Fibrinogen — degradation products
FDP
65120
Fitzgerald factor
FGF
65150
Flecainide
FLEC
66812
Fletcher factor
FF
65150
Fluorescent treponemal antibody — absorption test (FTA-ABS) — microbial antibody testing
FTA
69384
Fluoxetine
FLUX
66812
Foetal red blood cells — Kliehauer
KLEI
65162
Folate — red cell
RCF
66599
Follicle stimulating hormone (FSH)
FSH
66695
Fragile X
FXS
73300, 73305
Frozen section diagnosis of biopsy material
FS
72855–56
Fructosamine
FRUC
66557
Full blood examination
FBE
65070
Gamma glutamyl transpeptidase
GGT
66500
Gastric parietal cell — tissue antigens — antibodies
PCA
71119
Gastrin
GAST
66695
Gentamicin
66800
Gliadin IgA — tissue antigens — antibodies
GLIA
71163
Globulin
GLOB
66500
Glomerular basement membrane — tissue antigens — antibodies
GBA
71109
Glucagon
GLGO
66695
Glucose
GLUC
66500
Glucose — tolerance test
GTT
66542
Glycosylated haemoglobin (Hb Alc)
GHB
66551
Gold
AU
66672–73
Group B streptococcus — CSF antigens
STB
69364
Group B streptococcus — microbial antigen testing
STB
69364
Group P9 — simple basic pathology tests
73801–11
Growth hormone
GH
66695
Growth hormone — stimulation by exercise or L-dopa
GHSE
66686
Growth hormone — suppression by dexamethasone or glucose
GHSG
66686
Haematocrit
HCT
65070
Haemochromatosis
FEUP
66794
Haemoglobin
HB
65060
Haemoglobinopathy tests
HMGP
65081
Haemophilus influenzae — CSF antigens
HI
69364
Haemophilus influenzae — microbial antibody testing
HUS
69384
Haemophilus influenzae — microbial antigen testing
HI
69364
Haloperidol
HALO
66812
Haptoglobins
HGLB
66632
HDL cholesterol
HDLC
66536
Heart — tissue antigens — antibodies
AHE
71109
Heparin — test
HEPR
65144
Hepatitis B or C confirmatory test
HSVP
69484
Hepatitis C — detection
RNAC
69444
Hepatitis C — genotype
GHCV
69443
Hepatitis C — quantitation
THCV
69442
Hepatitis investigation — 3 markers
HEP3
69481
Hepatitis serology — in pregnancy
HEPP
69405–13
Hepatitis status or carriage — 1 marker
HEP1
69475
Hepatitis status or carriage — 2 markers
HEP2
69478
Hepatitis status or carriage — 3 markers
HEP3
69481
Herpes simplex virus — direct detection from clinical material
HSV
69364
Herpes simplex virus — investigation by culture
HSVC
69364
Herpes simplex virus — microbial antibody testing
HPA
69384
Herpes simplex virus — microbial antigen testing
HSV
69364
Heterophil antibodies
IM
65114
HIAA (hydroxyindoleacetic acid)
HIAA
66779
Histamine
HIAM
66779
Histone — tissue antigens — antibodies
AHI
71109
Histopathology of biopsy material
HIST
72813–36
Histoplasma — microbial antibody testing
HIP
69384
HIV — antiretroviral therapy
TVLT
69381
HIV — cerebrospinal fluid
CVLT
69382
HIV — monitoring
MVLT
69378
HLA typing — HLA class 1
HLA1
71149
HLA typing — HLA class 2
HLA2
71151
HLA typing — HLA-B27
HLAB
71147
HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA)
HMMA
66779
HMPG (hydroxy-methoxy phenylethylene glycol)
HMPG
66779
Homovanillic acid
HVA
66779
Hormone receptor assay — breast
HRA
66662
Hormone receptor assay — ovary
HRO
66662
Hormones — stimulation by exercise or L-dopa
GHSE
66686
Hormones — 11 deoxycortisol
DCOR
66695
Hormones — adrenocorticotrophic hormone
ACTH
66695
Hormones — aldosterone
ALDS
66695
Hormones — androstenedione
ANDR
66695
Hormones — calcitonin
CALT
66695
Hormones — cortisol
CORT
66695
Hormones — C-Peptide
CPEP
66695
Hormones — cyclic AMP
CAMP
66695
Hormones — dehydroepiandrosterone sulphate (DHEAS)
DHEA
66695
Hormones — dihydrotestosterone
DHTS
66695
Hormones — follicle stimulating hormone
FSH
66695
Hormones — gastrin
GAST
66695
Hormones — glucagon
GLGO
66695
Hormones — growth hormone
GH
66695
Hormones — growth hormone — stimulation by exercise or L-dopa
GHSE
66686
Hormones — growth hormone — suppression by dexamethasone or glucose
GHSG
66686
Hormones — hormone receptor assay — breast
HRA
66662
Hormones — hormone receptor assay — ovary
HRO
66662
Hormones — human chorionic gonadotrophin — detection for pregnancy diagnosis
HCGP
73527, 73529
Hormones — human chorionic gonadotrophin — quantitation
HCG
66650–53, 66750, 66751, 73529
Hormones — hydroxyprogesterone
OHP
66695
Hormones — insulin
INS
66695
Hormones — luteinizing hormone
LH
66695
Hormones — oestradiol
E2
66695
Hormones — oestriol
E3
66750, 66751
Hormones — oestrone
E1
66695
Hormones — parathyroid hormone
PTH
66695
Hormones — progesterone
PROG
66695
Hormones — prolactin
PROL
66695
Hormones — renin
REN
66695
Hormones — sex hormone binding globulin
SHBG
66695
Hormones — somatomedin
SOMA
66695
Hormones — suppression by dexamethasone or glucose
GHSG
66686
Hormones — testosterone
TES
66695
Hormones — urine steroid fraction or fractions
USF
66695
Hormones — vasoactive intestinal peptide
VIP
66695
Hormones — vasopressin
ADH
66695
Hormones and hormone binding proteins (see individual hormones and proteins)
66695
Huhner’s test
HT
73521
Human chorionic gonadotrophin — detection for pregnancy diagnosis
HCGP
73527, 73529
Human chorionic gonadotrophin — quantitation
HCG
66650–53, 66750, 66751, 73529
Human papillomaviruses
HPV
69486
HVA (homovanillic acid)
HVA
66779
Hydatid — microbial antibody testing
HYD
69384
Hydroxy methoxy phenylethylene glycol
HMPG
66779
Hydroxy-3-methoxymandelic acid (previously known as VMA)
HMMA
66779
Hydroxychloroquine
HOCQ
66812
Hydroxyindoleacetic acid
HIAA
66779
Hydroxyprogesterone
OHP
66695
Hydroxyproline
HYDP
66752
Imipramine
IMIP
66812
Immediate frozen section diagnosis of biopsy material
FS
72855–56
Immunocyto. 1-3 antibodies
ICC
73059, 73061
Immunocyto. 4+ antibodies
ICC1
73060
Immunoelectrophoresis and electrophoresis —characterisation of cryoglobulins
RYO
71059
Immunoelectrophoresis and electrophoresis —characterisation of paraprotein
PPRO
71059
Immunoglobulins — A
IGA
71066
Immunoglobulins — D
IGD
71074
Immunoglobulins — E (total)
IGE
71075–79
Immunoglobulins — G
IGG
71068
Immunoglobulins — G, 4 subclasses
SIGG
71073
Immunoglobulins — M
IGM
71072
Immunohistochemical investigation of biopsy material
HIS
72846–48
Infectious mononucleosis
IM
69384
Influenza A — microbial antibody testing
FLA
69384
Influenza B — microbial antibody testing
FLB
69384
Insulin
INS
66695
Insulin — tissue antigens — antibodies
AINS
71109
Insulin receptor antibodies — tissue antigens — antibodies
INSA
71109
Intercellular cement substance of skin — tissue antigens — antibodies
ICCS
71109
Intestinal disaccharidases
INTD
66680
Intrinsic factor — tissue antigens — antibodies
AIF
71109
Iron studies (iron, transferrin and ferritin)
IS
66596
Islet cell — tissue antigens — antibodies
AIC
71109
Isoelectric focussing and electrophoresis —characterisation of cryoglobulins
RYO
71059
Isoelectric focussing and electrophoresis —characterisation of paraprotein
PPRO
71059
Jo-1 — tissue antigens — antibodies
JO1
71119
Keratin — tissue antigens — antibodies
KERA
71119
Kleihauer test
KLEI
65162
Lactate
LACT
66500
Lactate — dehydrogenase
LDH
66500
Lactate — dehydrogenase isoenzymes
LDI
66641
Lamellar body phospholipid
LBPH
66749
Lead
PB
66665
Lecithin/sphingomyelin ratio (amniotic fluid)
LS
66749
Legionella pneumophila — serogroup 1 — microbial antibody testing
LP1
69384
Legionella pneumophila — serogroup 2 — microbial antibody testing
LP2
69384
Leishmaniasis — microbial antibody testing
LEI
69384
Leptospira — microbial antibody testing
LEP
69384
Leucocyte count
WCC
65070
Leucocyte count — 3 surface markers — blood, CSF, serous fluid
LMH3
71139
Leucocyte count — 3 surface markers — tissue
LMT3
71141
Leucocyte count — 6 surface markers — blood, CSF, serous fluid and tissue(s)
LMHT
71145
Leucocyte count — 6 surface markers — blood, CSF, serous fluid or tissue
LM6
71143
Leucocyte count — CD34 surface marker only — blood
LMCD34
71146
Lignocaine
LIGN
66800
Lip — cytology on specimens from
SMCY
73043
Lipase
LIP
66500
Lipid studies
FATS
66500
Lipoprotein subclasses — electrophoresis
LEPG
66539
Listeria — microbial antibody testing
LIS
69384
Lithium
LI
66800
Liver function tests
LFT
66515
Liver/kidney microsomes — tissue antigens — antibodies
LKA
71119
Lupus anticoagulant
LUPA
65132–37, 65142
Luteinizing hormone
LH
66695
Lymphocyte — tissue antigens — antibodies
ALY
71109
Lymphocytes — functional tests — 1 test
LF1
71127
Lymphocytes — functional tests — 2 tests
LF2
71129
Lymphocytes — functional tests — 3 tests
LF3
71131
Magnesium
MG
66500
Mammary serum antigen
MSA
66650
Manganese
MN
66669–70
Mantoux test
MANT
73811
Measles — microbial antibody testing
MEA
69384
Mercury
HG
66672–73
Metabolic bone disease
CBMB
66776
Metanephrines
MNEP
66779
Methadone
MTDN
66812
Methaemalbumin detection (Schumm’s test)
SCHM
65117
Methotrexate
MTTA
66812
Methsuximide
MSUX
66812
Methylphenobarbitone
MPBT
66812
Metronidazole
MRDZ
66812
Mexiletine (Mexitil)
MEX
66812
Mianserin
MIAS
66812
Microalbumin
MALB
66560
Microbial antibody testing — actinomycetes
ACT
69384
Microbial antibody testing — adenovirus
ADE
69384
Microbial antibody testing — aspergillus
ASP
69384
Microbial antibody testing — avian precipitins (bird fancier’s disease)
APP
69384
Microbial antibody testing — Blastomyces
BLM
69384
Microbial antibody testing — Bordetella pertussis
BOR
69384
Microbial antibody testing — Borrelia burgdorferi
BOB
69384
Microbial antibody testing — Brucella
BRU
69384
Microbial antibody testing — Campylobacter jejuni
CAM
69384
Microbial antibody testing — Candida
CAN
69384
Microbial antibody testing — Chlamydia
CHL
69384
Microbial antibody testing — Coccidioides
CCC
69384
Microbial antibody testing — Coxsackie B1-6
COX
69384
Microbial antibody testing — cryptococcus
CRY
69384
Microbial antibody testing — cytomegalovirus
CMV
69384
Microbial antibody testing — cytomegalovirus serology in pregnancy
CMVP
69384
Microbial antibody testing — dengue
DEN
69384
Microbial antibody testing — diphtheria
DIP
69384
Microbial antibody testing — echinococcus
ECC
69384
Microbial antibody testing — echo-coxsackie group
ECH
69384
Microbial antibody testing — Entamoeba histolytica
AMO
69384
Microbial antibody testing — Epstein Barr virus
EBV
69472–74
Microbial antibody testing — fluorescent treponemal antibody — absorption test
(FTA-ABS)
FTA
69384
Microbial antibody testing — Haemophilus influenzae
HUS
69384
Microbial antibody testing — herpes simplex virus
HPA
69384
Microbial antibody testing — Histoplasma
HIP
69384
Microbial antibody testing — Human Immunodeficiency Virus
69384
Microbial antibody testing — hydatid
HYD
69384
Microbial antibody testing — infectious mononucleosis
IM
69384
Microbial antibody testing — influenza A
FLA
69384
Microbial antibody testing — influenza B
FLB
69384
Microbial antibody testing — Legionella pneumophila — serogroup 1
LP1
69384
Microbial antibody testing — Legionella pneumophila — serogroup 2
LP2
69384
Microbial antibody testing — leishmaniasis
LEI
69384
Microbial antibody testing — Leptospira
LEP
69384
Microbial antibody testing — Listeria
LIS
69384
Microbial antibody testing — measles
MEA
69384
Microbial antibody testing — Micropolyspora faeni
MIC
69384
Microbial antibody testing — mumps
MUM
69384
Microbial antibody testing — Murray Valley encephalitis
MVE
69384
Microbial antibody testing — Mycoplasma pneumoniae
MYC
69384
Microbial antibody testing — Neisseria meningitidis
MEN
69384
Microbial antibody testing — Newcastle disease
NCD
69384
Microbial antibody testing — parainfluenza 1
PF1
69384
Microbial antibody testing — parainfluenza 2
PF2
69384
Microbial antibody testing — parainfluenza 3
PF3
69384
Microbial antibody testing — paratyphi
PTY
69384
Microbial antibody testing — pertussis
PER
69384
Microbial antibody testing — poliomyelitis
PLO
69384
Microbial antibody testing — Proteus OX 19
POX
69384
Microbial antibody testing — Proteus OXK
POK
69384
Microbial antibody testing — Q fever
QFF
69384
Microbial antibody testing — rapid plasma reagin test
RPR
69384
Microbial antibody testing — respiratory syncytial virus
RSV
69384
Microbial antibody testing — Ross River virus
RRV
69384
Microbial antibody testing — rubella
RUB
69384
Microbial antibody testing — Salmonella typhi (H)
SAH
69384
Microbial antibody testing — Salmonella typhi (O)
SAO
69384
Microbial antibody testing — Schistosoma
STO
69384
Microbial antibody testing — streptococcal serology — anti-DNASE B titre
ADNB
69384
Microbial antibody testing — streptococcal serology — anti-streptolysin O titre
ASOT
69384
Microbial antibody testing — Streptococcus pneumoniae
PCC
69384
Microbial antibody testing — tetanus
TET
69384
Microbial antibody testing — Thermoactinomyces vulgaris
THE
69384
Microbial antibody testing — thermopolyspora
TPS
69384
Microbial antibody testing — Toxocara
TOC
69384
Microbial antibody testing — toxoplasma
TOX
69384
Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)
TPHA
69384
Microbial antibody testing — Treponema pallidum haemagglutination test
TPHA
69384
Microbial antibody testing — trichinosis
TOS
69384
Microbial antibody testing — typhus, Weil-Felix
TYP
69384
Microbial antibody testing — Varicella zoster
VCZ
69384
Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)
VDRL
69384
Microbial antibody testing — Yersinia enterocolitica
YER
69384
Microbial antigen testing — Chlamydia
MCCH
69364
Microbial antigen testing — Clostridium difficile
CLDT
69363
Microbial antigen testing — group B streptococcus
STB
69364
Microbial antigen testing — Haemophilus influenzae
HI
69364
Microbial antigen testing — herpes simplex virus
HSV
69364
Microbial antigen testing — Neisseria gonorrhoeae
GON
69364
Microbial antigen testing — Neisseria meningitidis
NMG
69364
Microbial antigen testing — respiratory syncytial virus
RSVN
69364
Microbial antigen testing — Streptococcus pneumoniae
SPN
69364
Microbial antigen testing — Varicella zoster
VCZN
69364
Micropolyspora faeni
MIC
69384
Microscopic examination of — faeces for parasites
OCP
69336–39
Microscopic examination of — wet film material other than blood
MWFM
69300
Microscopy and culture of — material from nose, throat, eye or ear
MCSW
69303
Microscopy and culture of — material from skin
MCSK
69309
Microscopy and culture of — postoperative wounds, aspirates of body cavities
MCPO
69321
Microscopy and culture of — superficial sites
MCSS
69306
Microscopy and culture of — urethra, vagina, cervix or rectum
MCGR
69312
Microscopy and culture of — specimens of sputum
MCSP
69318
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 1 specimen
AFB1
69324
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 2 specimens
AFB2
69327
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria — 3 specimens
AFB3
69330
Microscopy and culture to detect pathogenic micro-organisms including chlamydia
MCCH
69364
Microscopy, culture, identification and sensitivity of urine
UMCS
69333
Mitochondria — tissue antigens — antibodies
MA
71119
Mouth — cytology on specimens from
SMCY
73043
Mumps — microbial antibody testing
MUM
69384
Murray Valley encephalitis — microbial antibody testing
MVE
69384
Mycobacteria microscopy and culture of sputum — 1 specimen
AFB 1
69324
Mycobacteria microscopy and culture of sputum — 2 specimens
AFB 2
69327
Mycobacteria microscopy and culture of sputum — 3 specimens
AFB 3
69333
Mycoplasma pneumoniae — microbial antibody testing
MYC
69384
Myoglobin
MYOG
66518
N-acetyl procainamide
NAPC
66812
Neisseria gonorrhoeae by NAA techniques and chlamydia by any method
CHGO
69364
Neisseria gonorrhoeae — microbial antigen testing
GON
69364
Neisseria meningitidis — antigens
NMG
69364
Neisseria meningitidis — microbial antibody testing
MEN
69384
Neisseria meningitidis — microbial antigen testing
NMG
69364
Netilmicin
66800
Neural tube defects and Down’s syndrome
NTDD
66750, 66751
Neuron — tissue antigens — antibodies
ANE
71109
Neutrophil cytoplasm — tissue antigens — antibodies
ANCA
71109
Neutrophil functions
NFT
71135
Newcastle disease — microbial antibody testing
NCD
69384
Nickel
NI
66672–73
Nipple discharge — cytology on specimens from
SMCY
73043
Nitrazepam
NITR
66812
Nordothiepin
NDIP
66812
Norfluoxetine
NFLE
66812
Nortriptyline
NORT
66812
Nose — cytology on specimens from
SMCY
73043
Nose — microscopy and culture of material from
MCSW
69303
Nuclear antigens — detection of antibodies to
ANA
71097
Oestradiol
E2
66695
Oestriol
E3
66750, 66751
Oestrone
E1
66695
Oligoclonal proteins
OGP
71062
Op/biopsy specimens — microscopy and culture of material from
MCPO
69321
Oral glucose challenge test — gestational diabetes
OGCT
66545
Oral glucose tolerance test — gestational diabetes
GTTP
66542
Osmolality, serum or urine
OSML
66563
Ovary — tissue antigens — antibodies
AOV
71109
Oxalate
OXAL
66752
Oxazepam
OXAZ
66812
PAA (phenyl acetic acid)
PAA
66779
Palmitic acid in amniotic fluid
PALM
66749
Pap smear
CCR
73053
Papanicolaou test
CCR
73053
Paracetamol
PARA
66800
Parainfluenza 1 — microbial antibody testing
PF1
69384
Parainfluenza 2 — microbial antibody testing
PF2
69384
Parainfluenza 3 — microbial antibody testing
PF3
69384
Paraprotein characterisation — by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focussing
PPRO
71059
Paraprotein characterisation — on concurrently collected serum or urine
PPSU
71060
Paraprotein quantitation — by electrophoresis
EPPI
71057
Paraquat
PARQ
66812
Parasites — microscopic examination of faeces
OCP
69336–39
Parathyroid hormone (PTH)
PTH
66695
Parathyroid — tissue antigens — antibodies
PTHA
71109
Paratyphi — microbial antibody testing
PTY
69384
Partial thromboplastin time
PTT
65120
Patient episode initiation fees
PEI
73901–15
Pentobarbitone
PENT
66812
Perhexiline
PHEX
66812
Pertussis — microbial antibody testing
PER
69384
Phenobarbitone
PHBA
66800
Phensuximide
PHEN
66812
Phenylacetic acid
PAA
66779
Phenytoin
PHEY
66800
Phosphate
PHOS
66500
Phosphatidylglycerol
PTGL
66749
Plasminogen
PLAS
65139
Platelet — aggregation
PLTG
65144
Platelet — count
PLTC
65070
Platelet — tissue antigens — antibodies
APA
71109
PM-Sc1 — tissue antigens — antibodies
PM1
71119
Poliomyelitis — microbial antibody testing
PLO
69384
Porphobilinogen in urine
UPG
66782
Porphyrins — quantitative test, 1 or more fractions
PR
66785
Porphyrins in urine — qualitative test
UPR
66782
Potassium
K
66500
Prealbumin
PALB
66632
Prednisolone
PRED
66812
Pregnancy serology — 1 test
MSP1
69405
Pregnancy serology — 2 tests
MSP2
69408
Pregnancy serology — 3 tests
MSP3
69411
Pregnancy serology — 4 tests
MSP4
69413
Pregnancy testing
73806
Pregnancy testing — diagnosis of Down’s syndrome and neural tube defect
NTDD
66750, 66751
Pregnancy testing — HCG detection
HCG
73527, 73529
Pregnancy testing — HCG quantitation
HCG
73529
Primidone
PRIM
66800
Procainamide
PCAM
66800
Progesterone
PROG
66695
Prolactin
PROL
66695
Propranolol
PPNO
66812
Prostate specific antigen
PSA
66655–59
Protein — C
PROC
65132–36, 65142, 65171
Protein — S
PROS
65132–36, 65142, 65171
Protein, quantitation of — alpha fetoprotein
AFP
66650–53, 66743, 66750, 66751
Protein, quantitation of — alpha-l-antitrypsin
AAT
66635
Protein, quantitation of — beta-2-microglobulin
BMIC
66629
Protein, quantitation of — caeruloplasmin
CPLS
66632
Protein, quantitation of — C-l esterase inhibitor
CEI
66644
Protein, quantitation of — classes or presence and amount of paraprotein by electrophoresis
EPPI
71057, 71058
Protein, quantitation of — ferritin (see also Iron studies)
FERR
66593
Protein, quantitation of — for Down’s syndrome/neural tube defect testing
NTDD
66750, 66751
Protein, quantitation of — haptoglobins
HGLB
66632
Protein, quantitation of — microalbumin
MALB
66560
Protein, total — quantitation of
PROT
66500
Proteus OX 19 — microbial antibody testing
POX
69384
Proteus OXK — microbial antibody testing
POK
69384
Prothrombin gene mutation
PGM
65168, 65174
Prothrombin time
PT
65120
Pyruvate
PVTE
66500
Q fever — microbial antibody testing
QFF
69384
Quinalbarbitone
QUIB
66812
Quinidine
QUIN
66800
Quinine
QNN
66812
Rapid plasma reagin test — microbial antibody testing
RPR
69384
RAST
RAST
71079
Rectum — microscopy and culture of material from
MCGR
69312
Red blood cells — Kleihauer
KLEI
65162
Red cell folate and serum B12
B12F
66602
Red cell folate and serum B12 and serum folate if required
B12F
66602
Red cell folate and serum folate
RCF
66599
Red cell porphyrins — qualitative test
RCP
66782
Referred specimen fee
73921
Renin
REN
66695
Reptilase test
REPT
65120
Respiratory syncytial virus — microbial antibody testing
RSV
69384
Respiratory syncytial virus — microbial antigen testing
RSVN
69364
Reticulin — tissue antigens — antibodies
RCA
71119
Reticulocyte count
RETC
65072
Rheumatoid factor
RF
71106
Rheumatoid factor — quantitation
RFQ
71106
Ross River virus — microbial antibody testing
RRV
69384
RSV (respiratory syncytial virus) — microbial antibody testing
RSV
69384
RSV (respiratory syncytial virus) — microbial antigen testing
RSVN
69364
Rubella — serology
RUB
69384
Salicylate (aspirin)
SALI
66800
Salivary gland — tissue antigens — antibodies
ASG
71109
Salmonella typhi (H) — microbial antibody testing
SAH
69384
Salmonella typhi (O) — microbial antibody testing
SAO
69384
Schistosoma — microbial antibody testing
STO
69384
Scl-70 — tissue antigens — antibodies
SCL
71119
Selenium
SE
66669–70
Semen examination
SEE
73523
Semen examination — for spermatozoa (post vasectomy)
SES
73521
Serology — in pregnancy (see Pregnancy serology)
Serotonin
5HT
66779
Serum — Bl2
B12
66599
Serum — folate (with Bl2 red cell folate)
B12F
66602
Serum — folate (with Bl2)
B12
66599
Sex hormone binding globulin
SHBG
66695
Skeletal muscle — tissue antigens — antibodies
SLA
71109
Skin — cytology
SMCY
73043
Skin — microscopy and culture of material from
MCSS
69306
Skin — microscopy, culture and Chlamydia of material from
MCSK
69309
Skin basement membrane — tissue antigens — antibodies
SKA
71109
Smooth muscle — tissue antigens — antibodies
SMA
71119
Snake venom
HISS
66623
Sodium
NA
66500
Solid tissue or tissues — chemical assays
ENZS
66683
Solid tissue or tissues — cytology of fine needle aspiration
FNCY
73049
Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of pathologist
FNCP
73051
Somatomedin
SOMA
66695
Sotalol
SALL
66812
Specific IgE or IgG antibodies
RAST
71079
Specimen referred fee
73921
Sperm antibodies
SAB
73525
Sperm antibodies — penetrating ability
SPA
73525
Sputum — cytology (1 specimen)
BFCY
73045
Sputum — cytology (3 specimens)
SPCY
73047
Sputum — for mycobacteria — 1 specimen
AFB1
69324
Sputum — for mycobacteria — 2 specimens
AFB2
69327
Sputum — for mycobacteria — 3 specimens
AFB3
69330
Sputum — microscopy and culture of specimens
MCSP
69318
Stelazine
STEL
66812
Steroid fraction or fractions in urine
USF
66695
Streptococcal serology — anti-DNASE B titre — microbial antibody testing
ADNB
69384
Streptococcal serology — anti-streptolysin O titre — microbial antibody testing
ASOT
69384
Streptococcus — Group B
STB
69364
Streptococcus pneumoniae — CSF antigens
SPN
69364
Streptococcus pneumoniae — microbial antibody testing
PCC
69384
Streptococcus pneumoniae — microbial antigen testing
SPN
69364
Strontium
SR
66672–73
Stypven test
STYP
65120
Sugar water test
SWT
65075
Sulthiame (Ospolot)
SUL
66812
Supplementary testing for Hepatitis C antibodies
HCST
69441
Syphilis serology
STS
69387
Testosterone
TES
66695
Tetanus — microbial antibody testing
TET
69384
Thalassaemia studies
TS
65078
Theophylline
THEO
66800
Thermoactinomyces vulgaris — microbial antibody testing
THE
69384
Thermopolyspora — microbial antibody testing
TPS
69384
Thiopentone
TOPO
66812
Thioridazine
THIO
66812
Throat — microscopy and culture of material from
MCSW
69303
Thrombin time
TT
65120
Thrombophilia testing (see individual thrombophilia tests)
Thyroglobulin
TGL
66650
Thyroglobulin — tissue antigens — antibodies
ATG
71109
Thyroid function tests (including TSH)
TFT
66719
Thyroid microsome — tissue antigens — antibodies
TMA
71109
Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)
TSH
66716
Thyroid stimulating hormone (if requested with other hormones referred to in item 66695)
TSH
66722–34
Tissue transglutaminase antibodies
TTG
71163
Tobramycin
66800
Total protein
PROT
66500
Toxocara — microbial antibody testing
TOC
69384
Toxoplasma — microbial antibody testing
TOX
69384
TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing
TPHA
69384
Treponema pallidum haemagglutination test — microbial antibody testing
TPHA
69384
Trichinosis — microbial antibody testing
TOS
69384
Triglycerides
TRIG
66500
Trimipramine
TRIM
66812
Troponin
TROP
66518
Tryptic activity in faeces
TAF
66677
TSH receptor antibody test — tissue antigens — antibodies
TSHA
71109
Tuberculosis
MANT
73811
Tumour markers — CA-15.3 antigen
CA15
66650
Tumour markers — CA-19.9 antigen
CA19
66650
Tumour markers — CA-125 antigen
C125
66650
Tumour markers — carcinoembryonic antigen
CEA
66650
Tumour markers — mammary serum antigen
MSA
66650
Tumour markers — prostate specific antigen
PSA
66656
Tumour markers — prostatic acid phosphatase — 1 or more fractions
ACP
66656
Tumour markers — thyroglobulin
TGL
66650
Typhus, Weil-Felix — microbial antibody testing
TYP
69384
Urate
URAT
66500
Urea
U
66500
Urea, electrolytes, creatinine
U&E
66515
Urethra — microscopy and culture of material from
MCGR
69312
Urine — acidification test
UAT
66587
Urine — catalase test
UCAT
73805
Urine — cystine (cysteine)
UCYS
66782
Urine — cytology — on 1 specimen
BFCY
73045
Urine — cytology — on 3 specimens
SPCY
73047
Urine — haemoglobin
UHB
66782
Urine — microscopy, culture, identification and sensitivity
UMCS
69333
Urine — porphobilinogen
UPG
66782
Urine — porphyrins — qualitative test
UPR
66782
Urine — steroid fraction or fractions
USF
66695
Urine — urobilinogen
UUB
66782
Vagina — microscopy and culture of material from
MCGR
69312
Vagina — cytology on specimens from
CVO
73057
Valproate (Epilim)
VALP
66800
Vancomycin
VAN
66800
Varicella zoster — microbial antibody testing
VCZ
69384
Varicella zoster — microbial antigen testing
VCZN
69364
Vasoactive intestinal peptide
VIP
66695
Vasopressin
ADH
66695
VDRL (Venereal Disease Research Laboratory) — microbial antibody testing
VDRL
69384
Viscosity of blood or plasma
VISC
65060
Vitamins — B12
B12
66599
Vitamins — D
VITD
66608
Vitamins — folate
RCF
66599
Vitamins — quantitation of A, B1, B2, B3, B6, C or E
VIT
66605
VMA (see HMMA)
Von Willebrand’s factor
VWF
65150
Von Willebrand’s factor antigen
VWA
65150
Warfarin
WFR
66812
Yersinia enterocolitica — microbial antibody testing
YER
69384
Zinc
ZN
66667–70
Part 5 Complexity levels for histopathology items
Specimen type
Complexity level
Adrenal resection, neoplasm
5
Adrenal resection, not neoplasm
4
Anus, all specimens not otherwise specified
3
Anus, neoplasm, biopsy
4
Anus, neoplasm, radical resection
6
Appendix
3
Artery, all specimens not otherwise specified
3
Artery, biopsy
4
Bartholin’s gland — cyst
3
Bile duct, resection — all specimens
6
Bone, biopsy, curettings or fragments — lesion
5
Bone, biopsy or curettings quantitation — metabolic disease
6
Bone, femoral head
4
Bone, resection, neoplasm — all sites and types
6
Bone marrow, biopsy
4
Bone — all specimens not otherwise specified
4
Brain neoplasm, resection — cerebello-pontine angle
4
Brain or meninges, biopsy — all lesions
5
Brain or meninges, not neoplasm — temporal lobe
6
Brain or meninges, resection — neoplasm (intracranial)
5
Brain or meninges, resection — not neoplasm
4
Branchial cleft, cyst
4
Breast, excision biopsy, guidewire localisation — non-palpable lesion
6
Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease — all specimen types
6
Breast, incision biopsy or needle biopsy, malignant neoplasm — all specimen types
4
Breast, microdochectomy
6
Breast tissue — all specimens not otherwise specified
4
Bronchus, biopsy
4
Carotid body — neoplasm
5
Cholesteatoma
3
Digits, amputation — not traumatic
4
Digits, amputation — traumatic
2
Ear, middle and inner — not cholesteatoma
4
Endocrine neoplasm — not otherwise specified
5
Extremity, amputation or disarticulation — neoplasm
6
Extremity, amputation — not otherwise specified
4
Eye, conjunctiva — biopsy or pterygium
3
Eye, cornea
4
Eye, enucleation or exenteration — all lesions
6
Eye — not otherwise specified
4
Fallopian tube, biopsy
4
Fallopian tube, ectopic pregnancy
4
Fallopian tube, sterilization
2
Fetus with dissection
6
Foreskin — new born
2
Foreskin — not new born
3
Gallbladder
3
Gallbladder and porta hepatis-radical resection
6
Ganglion cyst, all sites
3
Gum or oral mucosa, biopsy
4
Heart valve
4
Heart — not otherwise specified
5
Hernia sac
2
Hydrocele sac
2
Jaw, upper or lower, including bone — radical resection for neoplasm
6
Joint and periarticular tissue, without bone — all specimens
3
Joint tissue, including bone — all specimens
4
Kidney, biopsy including transplant
5
Kidney, nephrectomy transplant
5
Kidney, partial or total nephrectomy or nephroureterectomy — neoplasm
6
Kidney, partial or total nephrectomy — not neoplasm
4
Large bowel (including rectum), biopsy — all sites
4
Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung’s Disease
5
Large bowel, colostomy — stoma
3
Large bowel (including rectum), polyp
4
Large bowel, segmental resection — colon, not neoplasm
5
Large bowel (including rectum), segmental resection, neoplasm
6
Larynx, biopsy
4
Larynx, partial or total resection
5
Larynx, resection with nodes or pharynx or both
6
Lip biopsy — all specimens not mentioned
3
Lip wedge resection or local excision with orientation
4
Liver, hydatid cyst or resection for trauma
4
Liver, total or subtotal hepatectomy — neoplasm
6
Liver — all specimens not otherwise specified
5
Lung, needle or transbronchial biopsy
4
Lung, resection — neoplasm
6
Lung, wedge biopsy
5
Lung segment, lobar or total resection
6
Lymph node, biopsy — all sites
4
Lymph node, biopsy, for lymphoma or lymphoproliferative disorder
5
Lymph nodes, regional resection — all sites
5
Mediastinum mass
5
Muscle, biopsy
6
Nasopharynx or oropharynx, biopsy
4
Nerve, biopsy neuropathy
5
Nerve, neurectomy or removal of neoplasm
4
Nerve — not otherwise specified
3
Nose, mucosal biopsy
4
Nose or sinuses, polyps
3
Odontogenic neoplasm
5
Odontogenic or dental cyst
4
Oesophagus, biopsy
4
Oesophagus, diverticulum
3
Oesophagus, partial or total resection
6
Omentum, biopsy
4
Ovary with or without tube — neoplasm
5
Ovary with or without tube — not neoplasm
4
Pancreas, biopsy
5
Pancreas, cyst
4
Pancreas, subtotal or total with or without splenectomy
6
Parathyroid gland(s)
4
Penisectomy with node dissection
5
Penisectomy — simple
4
Peritoneum, biopsy
4
Pituitary neoplasm
4
Placenta — not third trimester
4
Placenta — third trimester, abnormal pregnancy or delivery
4
Pleura or pericardium, biopsy or tissue
4
Products of conception, spontaneous or missed abortion
4
Products of conception, termination of pregnancy
3
Prostate, radical resection
6
Prostate — all types of specimen not otherwise specified
4
Retroperitoneum, neoplasm
5
Salivary gland, Mucocele
3
Salivary gland, neoplasm — all sites
5
Salivary gland — all specimens not otherwise specified
4
Sinus, paranasal, biopsy
4
Sinus, paranasal, resection — neoplasm
6
Skin, biopsy — blistering skin diseases
4
Skin, biopsy — inflammatory dermatosis
4
Skin, biopsy — investigation of alopecia where serial horizontal sections are taken, except for male pattern baldness
5
Skin, biopsy — investigation of lymphoproliferative disorder
5
Skin, eyelid, wedge resection
4
Skin, local resection — orientation
4
Skin, resection of malignant melanoma or melanoma in situ
5
Skin — all specimens not otherwise specified including all neoplasms and cysts
3
Small bowel — biopsy, all sites
4
Small bowel, diverticulum
3
Small bowel, resection — neoplasm
6
Small bowel — all specimens not otherwise specified
5
Soft tissue, infiltrative lesion — extensive resections at least 5 cm in maximal dimension
6
Soft tissue, lipoma and variants
3
Soft tissue, neoplasm, not lipoma — all specimens
5
Soft tissue — not otherwise specified
4
Spleen
5
Stomach, endoscopic biopsy or endoscopic polypectomy
4
Stomach, resection, neoplasm — all specimens
6
Stomach — all specimens not otherwise specified
4
Tendon or tendon sheath, giant cell neoplasm
4
Tendon or tendon sheath — not otherwise specified
3
Testis, biopsy
5
Testis and adjacent structures, castration
2
Testis and adjacent structures, neoplasm with or without nodes
5
Testis and adjacent structures, vas deferens sterilization
2
Testis and adjacent structures — not otherwise specified
3
Thymus — not otherwise specified
5
Thyroglossal duct — all lesions
4
Thyroid — all specimens
5
Tissue or organ not otherwise specified, abscess
3
Tissue or organ not otherwise specified, haematoma
3
Tissue or organ not otherwise specified, malignant neoplasm with regional nodes
6
Tissue or organ not otherwise specified, neoplasm local
4
Tissue or organ not otherwise specified, pilonidal cyst or sinus
3
Tissue or organ not otherwise specified, thrombus or embolus
3
Tissue or organ not otherwise specified, veins varicosity
3
Tissue or organ — all specimens not otherwise specified
3
Tongue, biopsy
4
Tongue or tonsil, neoplasm local
5
Tongue or tonsil, neoplasm with nodes
6
Tonsil, biopsy — excluding resection of whole organ
4
Tonsil or adenoids or both
2
Trachea, biopsy
4
Ureter, biopsy
4
Ureter, resection
5
Urethra, biopsy
4
Urethra, resection
5
Urinary bladder, partial or total with or without prostatectomy
6
Urinary bladder, transurethral resection of neoplasm
5
Urinary bladder — all specimens not otherwise specified
4
Uterus, cervix, curettings or biopsy
4
Uterus, cervix cone, biopsy (including LEEP or LLETZ biopsy)
5
Uterus, endocervix, polyp
3
Uterus, endometrium, polyp
3
Uterus, with or without adnexa, malignant neoplasm — all specimen types not otherwise specified
6
Uterus with or without adnexa, neoplasm, Wertheim’s or pelvic clearance
6
Uterus and/or cervix — all specimens not otherwise specified
4
Vagina, biopsy
4
Vagina, radical resection
6
Vaginal mucosa, incidental
3
Vulva or labia, biopsy
4
Vulval, subtotal or total with or without nodes
6
